Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference

Rhea-AI Summary

Ligand Pharmaceuticals (LGND) CEO and CFO to participate in a fireside chat at the Barclays Healthcare Conference. The event is on March 14, 2024, in Miami.

SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in a fireside chat at the Barclays 26^th Annual Global Healthcare Conference in Miami on Thursday, March 14, 2024, at 10:45 a.m. Eastern Time.

Management will participate in one-on-one investor meetings during the conference. Investors interested in meeting with Ligand should contact their Barclays representative.

About Ligand Pharmaceuticals

Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Our business model seeks to generate value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Our business model is based on funding programs in mid- to late-stage drug development in return for economic rights and licensing our technology to help partners discover and develop medicines. We partner with other pharmaceutical companies to attempt to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate our revenue. Our Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. We have established multiple alliances, licenses and other business relationships with the world’s leading pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International. For more information, please visit www.ligand.com. Follow Ligand on X @Ligand_LGND.

We use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our website and our X account, in addition to following our press releases, SEC filings, public conference calls and webcasts.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240305561022/en/

Investors:

Michael Jeong

investors@ligand.com

(561) 214-4232

LifeSci Advisors

Bob Yedid

bob@lifesciadvisors.com

(516) 428-8577

Media:

Kellie Walsh

media@ligand.com

(914) 315-6072

Source: Ligand Pharmaceuticals Incorporated

When will Ligand Pharmaceuticals CEO and CFO participate in a fireside chat at the Barclays Healthcare Conference?

Ligand Pharmaceuticals CEO and CFO will participate in a fireside chat at the Barclays Healthcare Conference on March 14, 2024, in Miami.

What is the ticker symbol for Ligand Pharmaceuticals?

The ticker symbol for Ligand Pharmaceuticals is LGND.

Where will the Barclays Healthcare Conference take place?

The Barclays Healthcare Conference will take place in Miami.

How can investors schedule a meeting with Ligand Pharmaceuticals during the conference?

Investors interested in meeting with Ligand Pharmaceuticals should contact their Barclays representative to schedule a meeting during the conference.